Cancer biomarkers for targeted therapy

Area of Science:

• Oncology and Immunology
• Molecular Biology and Pharmacology

Background:

• Tumor-associated antigens (TAAs) are key targets for antibody-based cancer therapies, including monoclonal antibodies (MoAbs), antibody-drug conjugates, and chimeric antigen receptor (CAR)-T cells.
• Antibodies targeting CD19, CD20, CD33, and CD38 are established treatments for hematological malignancies, while others like CD123 and BCMA are targets for emerging immunotherapies.
• Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have revolutionized cancer immunotherapy, with ongoing research into agents targeting IDO, LAG3, TIM-3, TIGIT, and CD47.

Discussion:

• Small molecule inhibitors (SMIs) targeting tyrosine kinases (e.g., BCR-ABL, EGFR, ALK) and other oncogenic pathways (e.g., BCL-2, BRAF, PARP) are mainstays in treating various cancers.
• Systems biology approaches are employed to identify cancer-specific TAAs, such as CD33, to minimize off-tumor toxicities.
• The development of novel biomarkers and innovative designs and delivery methods for targeted agents is crucial for advancing cancer therapy.

Key Insights:

• Antibody-based therapies and immune checkpoint inhibitors represent significant progress in cancer treatment.
• Small molecule inhibitors have fundamentally altered the therapeutic landscape for numerous cancer types.
• Targeting specific TAAs and developing novel delivery systems are critical for enhancing efficacy and reducing toxicity.

Outlook:

• Continued exploration of novel immune checkpoint inhibitors and antibody targets will expand therapeutic options.
• Advancements in systems biology and targeted agent design promise more precise and effective cancer treatments.
• The search for new biomarkers and improved delivery methods will fuel the next generation of cancer therapies.